Johnson & Johnson Completes Acquisition of Abbott Medical Optics
Johnson & Johnson (J&J) announced that it has completed the acquisition of Abbott Medical Optics (AMO), a wholly owned subsidiary of Abbott. The all-cash $4.325 billion acquisition was originally announced Sept. 16, 2016 and includes ophthalmic products in three areas of patient care: cataract surgery, laser refractive surgery, and consumer eye health. These product lines will now join with the Acuvue Brand Contact Lenses business, and the combined organization will operate under the brand name Johnson & Johnson Vision (J&J Vision). Contact Lenses Today had the opportunity to speak about the acquisition with Ashley McEvoy, company group chair, Johnson & Johnson Consumer Medical Devices.
According to Ms. McEvoy, J&J believed AMO would be a good fit for several reasons, including AMO’s foothold in the ophthalmic surgery sector and the company’s contact lens care portfolio –areas in which J&J did not already have a presence. She also noted that the acquisition presented an ideal culture fit as well. “Both companies put science and technology in the forefront,” she noted.
The rebranded organization will be structured into two divisions, which will be overseen by Ms. McEvoy and her leadership team. Both divisions will be reported in the medical devices section of J&J. The Contact Lens Platform will include J&J’s Acuvue family of contact lenses as well as AMO's Blink RevitaLens Multi-Purpose Disinfecting Solution, Complete Multi-Purpose Solution Easy Rub Formula, Oxysept Disinfecting Solution/Neutralizer-Ultracare Formula, Ultrazyme Enzymatic Cleaner, Blink Contacts Lubricating Eye Drops, and Blink-N-Clean Lens Drops. The Contact Lens Platform will be led by Worldwide President Swami Raote, who previously served as vice president, Ethicon, Asia Pacific and area vice president, North Asia, Medical Devices for J&J.
Ms. McEvoy says the company is hoping to leverage its existing contact lens distribution channels worldwide to offer the AMO products to a greater number of practitioners and patients. “We are hoping to use our and AMO’s strong brand expertise in our respective areas to tap into those markets,” she said. “We see this as an opportunity to educate practitioners and patients with whom we are already doing business about the importance of good hygiene practices and optimal contact lens care.”
The Surgical Platform will consist of the following products from AMO: Catalys System laser cataract system, Whitestar Signature Pro Phacoeumulsification System, Compact Intuitiv System, StabilEyes Capsular Tension Ring, the Tecnics family of intraocular lenses, iFS Advanced Femtosecond Laser, iDesign Advanced WaveScan Studio System, Star S4 IR Excimer Laser, and the Healon family of viscoelastics. Tom Frinzi, who previously served as senior vice president of Abbott’s vision business, will lead the surgical division, also under the Worldwide President title.
Going forward, Ms. McEvoy says she hopes that this acquisition can help both the optometric and ophthalmic sides of the eyecare market. “J&J Vision hopes to be a bridge between optometry and ophthalmology,” she explained, “and that this leads to the scalable business model of the future.”